Abstract:BackgroundDuchenne Muscular Dystrophy (DMD) is the most common muscle disease in children, and there are no effective therapies for DMD or Becker Muscular Dystrophy (BMD). Currently, targeted gene therapy treatments have emerged. As a result, genetic diagnosis is the basis of treatment. In addition, genetic and prenatal diagnosis significantly reduces their incidence rates. This study combines the application of multiplex ligation-dependent probe amplification technology (MLPA) and "next-generation" sequencing technology (NGS) as the most economical and efficient method of diagnosis. Therefore, in the diagnosis of DMD/BMD, patients' MLPA data are first used to detect DMD gene deletions or duplications, and NGS and Sanger sequencing are then applied to exclude MLPA-negative samples. Meanwhile, polymerase chain reaction (PCR) is used to detect single exon deletions to exclude false-positives in MLPA caused by point mutations.MethodsIn this study, we recruited 1051 proband families of DMD from 2016 to 2018 and had access to information that could identify individual participants during or after data collection. Patients who were diagnosed with DMD were first tested by MLPA. MLPA results with single exon deletions were validated with PCR amplification and Sanger sequencing. The negative results of MLPA were further analysed with NGS and validated by Sanger sequencing. For novel missense mutations, phenotype-genotype correlations were analysed using PolyPhen2 and mutation taster. All methods were performed in accordance with the relevant guidelines and regulations.ResultsDMD mutations were identified in 1029 families (97.91%, 1029/1051). Large deletions, duplications, and small mutations accounted for 70.41% (740/1051), 8.28% (87/1051), and 19.12% (201/1051) of all cases, respectively. There were 205 small mutation types, 53 of which were novel. The rate of de novo mutations was 39.45% (187/474) and was higher in large duplications (49.53%, 157/317). Among 68 asymptomatic patients (< 3 years old) with unexplained persistent hyperCKaemia upon conventional physical examination, 63 were diagnosed as DMD/BMD according to genetic diagnosis.ConclusionOur results expand the spectrum of DMD mutations, which could contribute to the treatment of DMD/BMD and provide an effective diagnosis method. Thus, the combination of MLPA, NGS and Sanger sequencing is of great significance for family analysis, gene diagnosis and gene therapy.

Identification of Two Rare Mutations C.1318g>a and C.6438+2t>g in a Chinese DMD Family As Genetic Markers

Genetic Identification of Pathogenic Variations of the DMD Gene: a Retrospective Study from 10,481 Neonatal Patients Based on Next-Generation Sequencing Data

Comprehensive Genetic Diagnosis of Patients with Duchenne/Becker Muscular Dystrophy (DMD/BMD) and Pathogenicity Analysis of Splice Site Variants in the DMD Gene

Targeted Next-Generation Sequencing As a Comprehensive Test for Patients with and Female Carriers of DMD/BMD: a Multi-Population Diagnostic Study

Genetic analysis of 1051 Chinese families with Duchenne/Becker Muscular Dystrophy

DMD mutations in pediatric patients with phenotypes of Duchenne/Becker muscular dystrophy

Screening of Duchenne Muscular Dystrophy (DMD) Mutations and Investigating Its Mutational Mechanism in Chinese Patients.

Characteristics of Dystrophin Gene Mutations among Chinese Patients As Revealed by Multiplex Ligation–Dependent Probe Amplification

A De Novo Mutation in Dystrophin Causing Muscular Dystrophy in a Female Patient.

[Mutation analysis and prenatal diagnosis of sporadic DMD/BMD families].

Study on Duchenne muscular dystrophy gene mutation and prenatal diagnosis]

Three novel splicing mutations at 5' terminal of DMD gene corresponding to different phenotypes

Prenatal Diagnosis of Duchenne Muscular Dystrophy in 131 Chinese Families with Dystrophinopathy

Preimplantational Genetic Diagnosis and Mutation Detection in A Family with Duplication Mutation of Dmd Gene

[Analysis of Results of Prenatal Diagnosis for 67 Pedigrees Affected with Duchenne Muscular Dystrophy in the Central Plain Region of China].

DMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations

Population-Wide Duchenne Muscular Dystrophy Carrier Detection by CK and Molecular Testing

Genetic Variation Analysis and Treatment Strategy of 20 Patients with Dystrophin Gene Mutations

A Resolved Discrepancy Between Multiplex PCR and Multiplex Ligation‐dependent Probe Amplification by Targeted Next‐generation Sequencing Discloses a Novel Partial Exonic Deletion in the Duchenne Muscular Dystrophy Gene

Clinical, Molecular Pathological and Genetic Analysis of a Chinese Family with Dystrophinopathy

Limb Girdle Muscular Dystrophy 23 Caused by Compound Heterozygous Mutations of LAMA2 Gene